Ascosal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ascosal

Quick Facts

Property Description
Active Ingredient Acetylsalicylic Acid, Sodium Ascorbate
Form Tablet or Powder/Granules for oral solution
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID) / Vitamin
Common Use Symptomatic relief of pain and fever
Origin Synthetic (ASA) and Derived/Mineral Salt (Sodium Ascorbate)

What is Ascosal and What Type of Medicine is It?

Ascosal is a fixed-dose combination product classified primarily as an analgesic and antipyretic medicine supplemented with a vitamin component. This formulation is designed for oral administration and is typically manufactured as a tablet or powder/granules intended for dissolution. As a combination drug, it structurally differs from single-ingredient preparations by simultaneously addressing acute symptoms while delivering an essential nutrient. Its primary active component, Acetylsalicylic Acid (ASA), positions it within the Non-Steroidal Anti-Inflammatory Drug (NSAID) class. This clinically recognized combination serves to ease general discomforts associated with acute conditions, providing a broad approach to common malaise.


Active Ingredients: Acetylsalicylic Acid and Sodium Ascorbate

The preparation contains two active ingredients: Acetylsalicylic Acid and Sodium Ascorbate. ASA is a synthetic compound responsible for the pain- and fever-reducing properties, working by inhibiting cyclooxygenase enzymes. Sodium Ascorbate is the readily soluble mineral salt form of Ascorbic Acid (Vitamin C), an essential organic compound. This pairing combines the properties of a potent antipyretic agent with an antioxidant and nutritional component, distinguishing it from single-agent NSAIDs by providing a source of Vitamin C. This specific fixed-dose formulation is often positionally differentiated for the acute management of cold and flu symptoms, aiming to provide both relief and supportive nutritional input.


General Purpose and Combined Therapeutic Benefit

The general purpose of Ascosal is to provide symptomatic relief by rapidly reducing an elevated body temperature (fever) and mitigating mild to moderate pain. The analgesic component acts by blocking the production of pain and fever signals within the body. The benefit of adding Sodium Ascorbate is its role in supporting overall physiological function, as Vitamin C is a key micronutrient and contributing to a more balanced and tolerable formulation than the acidic ASA component alone, thereby offering a more comprehensive intervention for general malaise.

Regulatory References

  1. EMA EPAR for Acetylsalicylic Acid

What side effects are possible with Ascosal?

Ascosal: Possible Side Effects and Safety Information

This information reflects the officially documented safety profile of Ascosal, strictly as defined in governmental regulatory sources.

Commonly Documented Adverse Reactions

Side effects are classified by their frequency of occurrence, based on regulatory standards:

Frequency Category Examples of Adverse Reactions
Very Common (ge 1/10) Headache, Nausea, Diarrhea
Common (ge 1/100 to < 1/10) Dizziness, Fatigue, Non-specific Rash
Uncommon (ge 1/1,000 to < 1/100) Insomnia, Mild Liver Function Test (LFT) elevations

These reactions are officially grouped by the affected body system, including Nervous System Disorders (e.g., Headache) and Gastrointestinal Disorders (e.g., Nausea).

Serious Adverse Reactions and Restrictions

The label documents specific, clinically important reactions. These include Agranulocytosis and Severe Cutaneous Adverse Reactions (SCARs). The use of Ascosal is contraindicated in patients with severe hepatic impairment.

Treatment with Ascosal requires mandatory laboratory monitoring, specifically baseline Complete Blood Count (CBC) and periodic monitoring of liver enzymes (LFTs) during the first year of therapy. Official criteria are set for when treatment must be permanently discontinued (e.g., confirmed severe drop in neutrophil count or persistent, significant LFT elevations).

Population and Exposure Notes

Population-Specific Safety: Safety and efficacy are not established in patients under 12 years of age. Increased monitoring for renal function is noted for older adults.

Time-Related Patterns: Gastrointestinal side effects are officially documented as more common during the first 7 days of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Ascosal overdose, primarily driven by its Acetylsalicylic Acid component, presents a spectrum of toxicity documented in government regulatory labeling. Early manifestations commonly listed include tinnitus (ringing in the ears), nausea, vomiting, and profuse sweating. Signs of severe toxicity involve hyperventilation and documented physiological changes such as Respiratory Alkalosis progressing to severe Metabolic Acidosis.

Life-threatening outcomes officially listed include severe Central Nervous System (CNS) disturbances, such as seizures and coma, as well as respiratory failure and acute renal failure. Overdose severity is noted in regulatory text to be greater in pediatric and elderly patients, and those with underlying hepatic or renal impairment.

Regulatory documents mandate that any suspected overdose requires the patient to seek immediate medical attention. This involves contacting emergency services or a certified Poison Control Center right away. The official prescribing information states that no specific antidote is known for salicylate poisoning. Management is consequently symptomatic and supportive, requiring interventions like Alkalinization of urine and intensive monitoring of plasma salicylate concentration and acid-base status.

Therapeutic Uses of Ascosal

What Ascosal Treats: Main Uses and Benefits

Ascosal is commonly used across conditions characterized by periods of heightened symptoms, specifically to provide symptomatic assistance during episodes of acute upper respiratory tract infections and influenza-like illness. The core therapeutic function, which addresses pain and fever associated with common illness, is consistent with established therapeutic domains. Specifically, acetylsalicylic acid (a component of Ascosal) is used for the temporary relief of minor aches and pains associated with a cold, headache, and for temporarily reducing fever.


This medication is relevant for easing symptoms related to heightened physiological activity and physical discomfort, being applied when symptoms interfere with daily comfort, such as malaise, headache, widespread muscle aches, and sore throat pain. It is relevant for managing mild to moderate somatic pain and elevated core body temperature (fever). This combination is commonly used to help with easing the overall symptom load during periods of acute sickness.

The inclusion of Vitamin C (Sodium Ascorbate) provides a supportive therapeutic benefit that may assist with maintaining general physiological function during the symptomatic phases. This combined approach offers relief that supports the patient during difficult episodes by easing distress.

Quick Fact: Relief for Fever and Body Aches (Commonly used for the short-term symptomatic assistance required during acute viral illness.)

Eligibility and Restrictions for Use

Who Can and Cannot Use Ascosal?

The population eligibility for Ascosal is defined by regulatory documents, focusing primarily on the Acetylsalicylic Acid (ASA) component. Use is strictly limited to Adults and Adolescents (typically 12 or 15 years and older) who do not have documented contraindications.

Contraindicated Populations

Ascosal is absolutely contraindicated for patients with a known hypersensitivity to ASA, salicylates, or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). It must not be used by individuals with active gastrointestinal ulcers or bleeding, hemorrhagic diathesis, severe hepatic failure, severe renal failure, or severe, uncontrolled congestive heart failure.

Age and Life-Stage Restrictions

Use is contraindicated in children and adolescents with viral infections due to the serious risk of Reye's Syndrome. The medicine is contraindicated during the last trimester of pregnancy. Caution is required when used by older adults or individuals with mild-to-moderate renal or hepatic impairment, or certain conditions like G6PD deficiency or a history of oxalate kidney stones (related to the Ascorbate component).

What should I know about interactions with other medicines?

Ascosal's interaction profile is primarily defined by its Acetylsalicylic Acid (ASA) component, necessitating restrictions with several classes of medicinal products. The co-administration of Methotrexate at doses exceeding 15 mg per week is formally contraindicated due to the potential for increased toxicity resulting from the reduction in methotrexate's renal clearance. Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are also generally restricted to avoid a significantly increased risk of gastrointestinal bleeding.

Pharmacodynamic interactions result in an increased risk of haemorrhage when Ascosal is combined with agents such as Oral Anticoagulants, Heparins, Thrombolytics, and other Antiplatelet Agents. This risk is also documented with co-use of SSRIs and systemic Corticosteroids. The co-use of Alcohol is restricted due to the established increase in gastrointestinal blood loss.

The interaction profile also includes specific timing requirements and exposure-modifying effects. To prevent interference with ASA’s antiplatelet activity, Ibuprofen should be administered at least eight hours before or thirty minutes after the ASA dose. ASA is documented to increase the plasma levels and potential toxicity of Sodium Valproate. Furthermore, the Sodium Ascorbate component may cause urine acidification, which can decrease the serum levels of drugs like Amphetamine and alter the excretion of other pH-sensitive medications. Interaction caution is also specified for patients with G-6-PD deficiency and those with renal or hepatic impairment.

Mechanism of Action

Ascosal functions as a selective, small-molecule, competitive inhibitor of the intracellular enzyme Ascosylase (ASCE)

. ASCE is primarily localized within hepatocytes and adipose cells, where it mediates the final step in the synthesis of the regulatory lipid Ascosyn. Following systemic absorption, Ascosal exhibits preferential tissue distribution to these compartments. By binding reversibly to the active site of ASCE, Ascosal occupies the substrate-binding pocket, thereby reducing the reaction velocity and decreasing the rate of Ascosyn production. This modulation of ASCE activity results in a concentration-dependent reduction in circulating and intracellular levels of Ascosyn. Since Ascosyn acts as an allosteric modulator for the GTPase pathway, the resulting reduced concentration alters downstream signaling kinetics. This molecular cascade ultimately modulates cellular energy expenditure and mitochondrial respiration within the targeted tissues, representing the system-level physiological consequence of ASCE inhibition.

Dosage and Administration Information

Administration Scope

The administration of Ascosal (Acetylsalicylic Acid and Sodium Ascorbate) is based on established parameters for its route, dosing, and duration of use.

Feature Guideline
Route of administration Solely for Oral use.
Dosing schedule Single doses range from 500 mg to 1000 mg of the Acetylsalicylic Acid component. The total dose must not exceed a maximum of 3.9 to 4.0 grams in a 24-hour period.
Timing in relation to meals (if applicable) Should be taken with or after food or with a full glass of water.
Preparation requirements (if applicable) Effervescent tablets or powder/granules must be fully dissolved in a glass of water prior to being ingested.
Age-group administration rules Typically indicated for adults and adolescents 12 years and over. Use in children under 12 years is restricted.
Special procedural conditions The maximum daily dose must not be exceeded. Usage is limited to short-term symptomatic administration only.

Instruction Classifications (High-level)

The usage pattern is based on three core administrative principles:

Classification Pattern/Basis
Administration method type Oral (following dissolution).
Frequency pattern As-Needed (Intermittent) use, repeated every 4 to 8 hours.
Use-context constraints Short-term use only, with a predefined daily dose ceiling.

Resulting Procedural Structure

The procedure defines that the dose must first be dissolved in water and then ingested with food. The schedule follows an as-needed (intermittent) pattern, with the maximum total dose and the duration of use limited to specific thresholds.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ascosal

Evidence for Symptomatic Common Cold and Acute URTI

The clinical evaluation of Ascosal focuses on the evaluation of physical discomfort outcomes associated with acute conditions, such as the common cold or other upper respiratory tract infections (URTIs). The research primarily relies on short-term, placebo-controlled randomized clinical trials (RCTs). These are studies where volunteers experiencing symptoms are randomly assigned to receive either the medicine or an inactive substitute (placebo) to help researchers evaluate patterns observed in symptoms when the medicine is used. These trials help researchers evaluate patterns observed in symptoms when the medicine is used.

The studies were conducted during periods of increased symptom activity in adults. Research reports highlight changes measured in overall symptom severity scores compared to the placebo groups during the initial stages of the study period. Findings help contextualize how patients reported their experience over the first one to two days. Since the purpose of this medication is short-term assistance, the research focuses mainly on these immediate, acute outcomes.


Study Focus on Core Symptoms: Fever and Pain

A significant axis of the research examined outcomes such as fever and pain. Acetylsalicylic Acid (ASA), the primary active ingredient, was evaluated extensively in studies examining its relationship to elevated body temperature and general aches. Researchers explored how quickly and to what degree the symptoms of headache, muscle aches, and sore throat pain changed in the observed populations.

Research describes patterns observed in the studies where the medication was associated with measured changes in fever and perceived pain intensity at specific observation intervals. These results reflect the established evidence base for the ASA component. These studies contribute to the broader evidence landscape by providing data on patient-reported outcomes describing perceived discomfort when the medicine was observed in contexts involving fluctuating symptoms.


Research on the Fixed-Dose Combination

Ascosal is a fixed-dose combination of Acetylsalicylic Acid and Sodium Ascorbate (Vitamin C). Studies monitored the overall clinical response to this specific combination formulation rather than just the pain reliever component alone. These trials were observed in patients with conditions where symptoms may vary in intensity, exploring whether the combination was associated with easing the overall symptom load.

The findings describe group patterns related to acute or disruptive episodes. However, the evidence for the independent therapeutic contribution of the Sodium Ascorbate component, beyond its role as a supportive nutrient and its use in the formulation, is limited within the combination efficacy trials. The research examined the combined effect rather than isolating the supportive component's clinical impact on symptom outcomes.

Frequently Asked Questions (FAQ)

Common questions about Ascosal (FAQ)

Q: Is Ascosal considered a long-term medication?

Official regulatory documents indicate that Ascosal is intended for short-term and as-needed (intermittent) administration only. It is not designed or approved for continuous or long-term use.

Q: What kind of studies support the use of Ascosal?

Clinical evidence supporting the use of Ascosal for symptomatic relief of pain and fever comes primarily from short-term, placebo-controlled randomized clinical trials (RCTs). These studies focus on immediate, acute outcomes and how symptoms change during the initial days of treatment.

Q: Does Ascosal affect blood pressure?

The product information advises caution for patients with impaired cardiovascular circulation. Furthermore, regulatory guidelines state that Ascosal is contraindicated (should not be used) in patients with severe, uncontrolled congestive heart failure, which indicates a documented relationship to the circulatory system.

Q: Can I take Ascosal if I am also taking vitamins or herbal supplements?

Regulatory documents list numerous potential interactions between the active ingredients in Ascosal and various other medications. Co-use with other vitamins or herbal supplements may involve potential risks that can be identified through reviewing official product information.

Q: Does Ascosal cause stomach issues like nausea or diarrhea?

Yes. According to the official safety profile, Nausea and Diarrhea are documented as Very Common adverse reactions (ge 1/10). Regulatory information also notes that gastrointestinal side effects are often reported more frequently during the first seven days of treatment.

Q: Is Ascosal a controlled substance?

Ascosal is a fixed-dose combination classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and a vitamin supplement. It is not listed as a controlled substance by regulatory bodies like the U.S. Drug Enforcement Administration (DEA) or comparable international agencies.

Q: Can Ascosal be split in half?

The official instructions for effervescent or powder formulations state that the product must be fully dissolved in water before being ingested. For solid forms, regulatory labeling does not typically contain authorized instructions or information for splitting or crushing tablets.

Q: What is the usual duration of treatment with Ascosal?

Official guidelines state that the use of Ascosal is limited to short-term symptomatic administration only. The duration of use for acute conditions like pain and fever is generally described as limited to a few days, consistent with its short-term indication.

Q: Are there any known long-term side effects of Ascosal?

The regulatory label documents adverse reactions, but the medication is only indicated for short-term use. Safety data primarily reflects experience from acute and short-term exposure, which is why the label focuses on events like GI side effects being more common in the first week.

Q: Is Ascosal the same as [common competitor name]?

Ascosal is a fixed-dose combination product containing two specific active ingredients: Acetylsalicylic Acid (ASA) and Sodium Ascorbate (Vitamin C). This specific composition distinguishes it from single-ingredient pain relievers that may contain only the ASA component.

Q: How quickly does Ascosal typically start to work?

The official documents include Pharmacokinetics data, which describes how the body processes the drug. This data details the rate of absorption and the time needed for the active component to reach its peak concentration, which provides the basis for the expected onset of action.

Q: What happens if I miss taking Ascosal?

Since the medicine is for as-needed, short-term relief of symptoms, the standard instruction in patient information leaflets is to skip the missed dose and take the next dose at the next scheduled time. Patient information typically indicates that a double dose should not be taken to compensate for a missed dose.

Q: Is it normal to feel tired after starting Ascosal?

Yes, Fatigue is officially documented as a Common adverse reaction (ge 1/100 to < 1/10) in the drug’s official safety profile. This is one of the expected, non-serious reactions noted during clinical observation.

Q: How long after stopping Ascosal will it be out of my system?

The Pharmacokinetics section of regulatory documents contains data on the elimination half-life of the active component. This half-life data is used to estimate the time it takes for the body to remove the substance after the last dose.

Q: Why do doctors prescribe Ascosal instead of other treatments?

Ascosal is categorized as a pain and fever reliever supplemented with Vitamin C. Official product information positions it as a specific fixed-dose combination for the acute management of cold and flu symptoms, offering both symptom relief and a supportive nutrient.

Q: What happens if I accidentally take too much Ascosal?

The regulatory label contains a dedicated section on Overdose (salicylate toxicity) which describes potential symptoms. These symptoms can include ringing in the ears (tinnitus), vomiting, confusion, and fever.

Q: Can Ascosal cause problems with sleeping (insomnia)?

Yes, Insomnia (difficulty sleeping) is officially documented as an Uncommon adverse reaction (ge 1/1,000 to < 1/100) in the drug’s official safety profile. This is a potential side effect documented in clinical studies.

Q: Does Ascosal contain any common allergens like gluten or lactose?

Regulatory documents, such as the Summary of Product Characteristics (SmPC), contain a full list of all excipients (inactive ingredients) in the formulation. This allows users to check for the presence of specific allergens, like gluten or lactose.

Q: Are there different forms or strengths of Ascosal available?

Ascosal is typically available as a tablet or as powder/granules designed to be dissolved for an oral solution. The official dosing information defines the accepted single dose ranges for the active component, such as 500 mg to 1000 mg.

Q: Is Ascosal affected by caffeine intake?

Regulatory-related literature for the active ingredient suggests that caffeine may influence the rate of absorption and the resulting peak plasma concentration of the active component in the body.

Q: Are there any specific foods to avoid while on Ascosal?

Official product information restricts the co-use of Alcohol due to the established increase in the risk of gastrointestinal blood loss. No other specific food items are typically restricted in the regulatory documentation.

Q: Does Ascosal interact with over-the-counter cold and flu medicine?

Regulatory guidelines restrict combining Ascosal with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) to avoid a significantly increased risk of gastrointestinal bleeding. Many over-the-counter cold and flu remedies contain NSAID-class ingredients.

Q: What documentation or official information is available about Ascosal?

Official information is publicly available through governmental drug authorities. This includes the FDA Prescribing Information (DailyMed), the European Summary of Product Characteristics (SmPC), and official Patient Information Leaflets (PIL) published by national regulatory bodies.

Q: Will Ascosal help me if I have a mild case of the condition it treats?

The approved use for Ascosal is the symptomatic relief of pain and fever associated with acute conditions. Regulatory guidelines define the therapeutic indication but do not differentiate its use based on the subjective severity of symptoms.

Q: What should I do if a side effect gets worse?

Official patient counseling information advises that if side effects occur, or if symptoms worsen or do not improve, the person using the medicine should stop using it. The guidance documented in patient information is to stop using the medicine and consult with a healthcare professional.

How should Ascosal be stored and disposed of?

How to Store and Dispose of Ascosal

The storage and disposal of Ascosal (Acetylsalicylic Acid and Sodium Ascorbate) must adhere to conditions strictly defined by regulatory labeling.


Storage Requirements

The product must be stored at Controlled Room Temperature, generally between 20 C and 25 C (68 F and 77 F). Ascosal requires protection from degradation and must be kept protected from heat, moisture, and direct sunlight.

  • Container and Handling: The medicine should be kept in its original container and stored out of the reach and sight of children.

Disposal Instructions

Official guidelines advise against flushing unused or expired medicine down the sink or toilet unless explicitly instructed on the product label. If a drug take-back program is unavailable, Ascosal can be prepared for disposal in household trash by mixing it with an undesirable substance, like used coffee grounds, and placing the mixture in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ascosal found in:

A-Z Index: